Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M8AA
|
|||
| Drug Name |
PMID28394193-Compound-45
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
PFIZER INC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H19N3O3
|
|||
| Canonical SMILES |
CC1=CC(=C(C(=O)N1)CN2CCC3=C(C2=O)C(=C(C=C3)OC)C#N)C
|
|||
| InChI |
1S/C19H19N3O3/c1-11-8-12(2)21-18(23)15(11)10-22-7-6-13-4-5-16(25-3)14(9-20)17(13)19(22)24/h4-5,8H,6-7,10H2,1-3H3,(H,21,23)
|
|||
| InChIKey |
SJAPTZBKLVFZLU-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Enhancer of zeste homolog 2 (EZH2) | Target Info | Inhibitor | [1] |
| EZH2 Y641N mutant (EZH2 Y641N) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Enhancer of zeste homolog 2 (EZH2) | Target's Patent Info | [1] | |
| EZH2 Y641N mutant (EZH2 Y641N) | Target's Patent Info | [1] | ||
| KEGG Pathway | MicroRNAs in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | PRC2 methylates histones and DNA | |||
| Oxidative Stress Induced Senescence | ||||
| PKMTs methylate histone lysines | ||||
| WikiPathways | Interactome of polycomb repressive complex 2 (PRC2) | |||
| Endoderm Differentiation | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Histone Modifications | ||||
| Cell Differentiation - meta | ||||
| miRs in Muscle Cell Differentiation | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.